Immunological and translational key challenges in systemic lupus erythematosus: A symposium update

IF 4.7 Q2 IMMUNOLOGY Journal of Translational Autoimmunity Pub Date : 2023-01-01 DOI:10.1016/j.jtauto.2023.100199

Yves Renaudineau , Sylviane Muller , Christian M. Hedrich , Dominique Chauveau , Julie Bellière , Sébastien De Almeida , Jan Damoiseaux , Marc Scherlinger , Jean Charles Guery , Laurent Sailler , Chloé Bost

{"title":"Immunological and translational key challenges in systemic lupus erythematosus: A symposium update","authors":"Yves Renaudineau , Sylviane Muller , Christian M. Hedrich , Dominique Chauveau , Julie Bellière , Sébastien De Almeida , Jan Damoiseaux , Marc Scherlinger , Jean Charles Guery , Laurent Sailler , Chloé Bost","doi":"10.1016/j.jtauto.2023.100199","DOIUrl":null,"url":null,"abstract":"<div><p>The first LBMR-Tim (Toulouse Referral Medical Laboratory of Immunology) symposium convened on December 16, 2022 in Toulouse, France to address challenging questions in systemic lupus erythematosus (SLE). Special focus was put on (i) the role played by genes, sex, TLR7, and platelets on SLE pathophysiology; (ii) autoantibodies, urinary proteins, and thrombocytopenia contribution at the time of diagnosis and during follow-up; (iii) neuropsychiatric involvement, vaccine response in the COVID-19 era, and lupus nephritis management at the clinical frontline; and (iv) therapeutic perspectives in patients with lupus nephritis and the unexpected adventure of the Lupuzor/P140 peptide. The multidisciplinary panel of experts further supports the concept that a global approach including basic sciences, translational research, clinical expertise, and therapeutic development have to be prioritized in order to better understand and then improve the management of this complex syndrome.</p></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"6 ","pages":"Article 100199"},"PeriodicalIF":4.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090709/pdf/main.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Autoimmunity","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589909023000126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

The first LBMR-Tim (Toulouse Referral Medical Laboratory of Immunology) symposium convened on December 16, 2022 in Toulouse, France to address challenging questions in systemic lupus erythematosus (SLE). Special focus was put on (i) the role played by genes, sex, TLR7, and platelets on SLE pathophysiology; (ii) autoantibodies, urinary proteins, and thrombocytopenia contribution at the time of diagnosis and during follow-up; (iii) neuropsychiatric involvement, vaccine response in the COVID-19 era, and lupus nephritis management at the clinical frontline; and (iv) therapeutic perspectives in patients with lupus nephritis and the unexpected adventure of the Lupuzor/P140 peptide. The multidisciplinary panel of experts further supports the concept that a global approach including basic sciences, translational research, clinical expertise, and therapeutic development have to be prioritized in order to better understand and then improve the management of this complex syndrome.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

系统性红斑狼疮的免疫学和翻译的关键挑战:研讨会更新

首届LBMR-Tim(图卢兹转诊免疫医学实验室)研讨会于2022年12月16日在法国图卢兹召开，旨在解决系统性红斑狼疮(SLE)的挑战性问题。特别关注(i)基因、性别、TLR7和血小板在SLE病理生理中的作用;(ii)自身抗体、尿蛋白和血小板减少症在诊断和随访期间的贡献;(iii) 2019冠状病毒病(COVID-19)时代的神经精神病学参与、疫苗反应和狼疮性肾炎的临床一线管理;(iv)狼疮性肾炎患者的治疗前景和Lupuzor/P140肽的意外冒险。多学科专家小组进一步支持这一概念，即必须优先考虑包括基础科学、转化研究、临床专业知识和治疗开发在内的全球方法，以便更好地了解并改进这一复杂综合征的管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊